Semaglutide for managing overweight and obesity - guidance (TA875)
NICE recommends semaglutide as an option for weight loss alongside a reduced-calorie diet and increased physical activity in adults with ≥1 weight-related comorbidity and a BMI ≥35kg/m2 or 30-34.9 kg/m2 and meet the criteria for referral to specialist weight management services.
Source:
National Institute for Health and Care Excellence
SPS commentary:
Criteria for referral to specialist weight management services are outlined in NICE’s guideline on obesity: identification, assessment and management .
Other recommendations for use include maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and consideration to stop treatment if less than 5% of the initial weight has been lost after 6 months of treatment.